Price
CHART BY
Frequently asked questions
What is Natera's market capitalization?
The market capitalization of Natera is $21.37B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Natera?
Natera's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.774. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Natera's stock?
Currently, 22 analysts cover Natera's stock, with a consensus target price of $181.37. Analyst ratings provide insights into the stock's expected performance.
What is Natera's revenue over the trailing twelve months?
Over the trailing twelve months, Natera reported a revenue of $1.53B.
What is the EBITDA for Natera?
Natera's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$204.90M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Natera?
Natera has a free cash flow of -$33.19M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Natera have, and what sector and industry does it belong to?
Natera employs approximately 3,293 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
What is the free float of Natera's shares?
The free float of Natera is 124.68M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $21.37B
- EPS (TTM)
- -$1.774
- Free Float
- 124.68M
- Revenue (TTM)
- $1.53B
- EBITDA (TTM)
- -$204.90M
- Free Cashflow (TTM)
- -$33.19M
Pricing
- 52W span
- $58.68$175.27
Analyst Ratings
The price target is $181.37 and the stock is covered by 22 analysts.
Buy
20
Hold
1
Sell
1
Information
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.
- Employees
- 3,293
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- ISIN
- US6323071042
- Primary Ticker
- NTRA